CN Patent

CN101330917A — 固定比率的联合用药治疗实体瘤

Assigned to Jazz Pharmaceuticals Therapeutics Inc · Expires 2008-12-24 · 17y expired

What this patent protects

此处提供了给予包含固定非拮抗摩尔比的依立替康和氟尿苷的药物组合物治疗癌症的方法。这种方法对治疗晚期实体瘤的癌症患者尤为有效。

USPTO Abstract

此处提供了给予包含固定非拮抗摩尔比的依立替康和氟尿苷的药物组合物治疗癌症的方法。这种方法对治疗晚期实体瘤的癌症患者尤为有效。

Drugs covered by this patent

Patent Metadata

Patent number
CN101330917A
Jurisdiction
CN
Classification
—
Expires
2008-12-24
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.